Jazz Pharmaceuticals plc (JAZZ)
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.
Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday.
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?
Investors need to pay close attention to Jazz (JAZZ) stock based on the movements in the options market lately.
Jazz (JAZZ) Upgraded to Buy: Here's Why
Jazz (JAZZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
The mean of analysts' price targets for Jazz (JAZZ) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View
JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents.
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.61 per share, beating the Zacks Consensus Estimate of $5.47 per share. This compares to earnings of $4.84 per share a year ago.
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
Jazz Pharmaceuticals plc JAZZ reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and Rylaze.
